Loading...
•
Dec 31, 2022
Immunome Q4 2022 Earnings Report
Reported financial results for the fourth quarter ended December 31, 2022.
Key Takeaways
Immunome reported financial results for the fourth quarter ended December 31, 2022, and provided a corporate update, highlighting their strategic collaboration with AbbVie.
Strategic collaboration with AbbVie highlighted the disruptive nature of Immunome's discovery platform.
The company is advancing its pipeline, including an IND submission for IMM-ONC-01.
Immunome is working closely with Abbvie on their collaboration.
The company is focused on discovering and developing therapeutics in oncology internally and in collaboration with partners.
Forward Guidance
Immunome looks forward to continuing to execute on its momentum throughout the upcoming year as it advances its pipeline and works closely with Abbvie on their collaboration.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...